Pharvaris reported that deucrictibant, its oral bradykinin B2 receptor antagonist, met primary and secondary endpoints in a pivotal Phase 3 study as an on‑demand treatment for hereditary angioedema (HAE). The company said the pill produced rapid symptom relief—reporting a median time to onset around 1.28 hours—and plans to file with the FDA in the first half of 2026. Executives positioned the result as a direct commercial challenge to KalVista’s recently approved oral competitor and to injectable on‑demand therapies. Pharvaris highlighted faster complete symptom resolution in its aggregated analyses compared with available comparators, while noting head‑to‑head data are not available. The Phase 3 success clears a major regulatory milestone and sets up a filing that could reshape the competitive landscape for on‑demand HAE medicines. Investors and payers will now focus on safety follow‑up, labeling expectations, and how Pharvaris differentiates in an expanding HAE market.